Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

NICE backs Johnson & Johnson's Darzalex (daratumumab) quadruplet for newly diagnosed transplant-ineligible multiple myeloma following Ph3 trial
Antibody, cancer, monoclonal antibody, multiple myeloma, CD38 target, combination therapy - Read more

AstraZeneca Pharma India wins CDSCO approval for Enhertu (trastuzumab deruxtecan) plus pertuzumab as first-line HER2-positive unresectable or metastatic breast cancer treatment
Antibody-drug conjugate, cancer, breast cancer, HER2-positive, trastuzumab deruxtecan, combination therapy - Read more

Servier, n-Lorem Foundation partner on ASO therapies for rare neurological disorders
Research collaboration, rare disease, neurological, antisense oligonucleotide, drug discovery - Read more

Collaborative Drug Discovery, Kiin Bio integrate CDD Vault with KiinOS to streamline drug discovery workflows
Research collaboration, AI/ML, drug discovery, data analytics, R&D - Read more

Formosa Pharmaceuticals, Samil Pharmaceuticals license clobetasol ophthalmic suspension for Vietnam, including upfront payment and milestones
Licensing deal, ophthalmology, small molecule, milestone payments, royalties - Read more

GENESIS Pharma expands commercial partnership with Alnylam Pharmaceuticals for RNAi therapeutics to Nordic region
Commercial partnership, rare disease, RNAi therapeutics, cardiomyopathy, commercialization - Read more

Laekna, Vasque Bio sign exclusive license for LAE118, $10M upfront, $517M milestones
Licensing deal, oncology, small molecule, milestone payments, royalties, equity investment - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Caribou Biosciences reports Ph1 (vispa-cel) 17.1-month median progression-free survival in second-line large B cell lymphoma ahead of Ph3
Cell therapy, cancer, CAR-T, allogeneic CAR-T, large B cell lymphoma, CD19 - Read more

Takeda's (zasocitinib) beats Bristol Myers Squibb's Sotyktu in Ph3 head-to-head trial for plaque psoriasis
Small molecule, autoimmune, TYK2 inhibitor, plaque psoriasis, head-to-head trial - Read more

Johnson & Johnson reports positive Phase 2/3 Imaavy (nipocalimab-aahu) data in warm autoimmune haemolytic anaemia, supporting FDA filing with priority review status
Antibody, autoimmune, monoclonal antibody, warm autoimmune haemolytic anaemia, FcRn blocker, nipocalimab - Read more

Alphamab Oncology's Anbenitamab meets Ph3 primary endpoint in HER2-positive advanced breast cancer
Antibody, cancer, monoclonal antibody, breast cancer, HER2, combination therapy - Read more

Parabilis Medicines reaches $3.7B market cap after record-breaking $670M biotech IPO and strong NASDAQ debut performance
Oncology, peptide therapeutics, intracellular targets, clinical-stage - Read more

Kardigan plans $320M IPO to advance four cardiovascular pipeline assets
Cardiovascular, small molecule, antisense oligonucleotide, clinical-stage, rare disease - Read more

Beren Therapeutics raises $300M, supports potential adrabetadex launch for Niemann-Pick disease type C
Rare disease, small molecule, clinical-stage, neurology - Read more

China updates Good Clinical Practice guideline to boost biotech innovation, effective September 1
Clinical trial guidelines, drug development, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Genentech restructures gRED unit, closing infectious disease and physiological chemistry teams, departing top executives
Cell therapy, infectious disease, operational, cost reduction - Read more

Bausch + Lomb lays off 119 Missouri workers amid phased surgical product production transfer
Ophthalmic surgical devices, ophthalmology, cost reduction, operational - Read more

Pfizer CEO Bourla warns Germany's healthcare reform plan threatens future investments in the country
Pharmaceutical industry, healthcare reform, investment, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here